logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial

Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A,  et al.
2010-11-08 • Lancet
2010-11-08 • Lancet
Severe malaria is a major cause of childhood death and often the main reason for paediatric hospital admission in sub-Saharan Africa. Quinine is still the established treatment of choice...
Journal Article
|
Research

Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis

WorldWide Antimalarial Resistance Network Methodology Study Group, Dahal P, Simpson JA, Abdulla S, Achan J,  et al.
2019-07-05 • Malaria Journal
2019-07-05 • Malaria Journal
BACKGROUND
Therapeutic efficacy studies in uncomplicated Plasmodium falciparum malaria are confounded by new infections, which constitute competing risk events since they can potenti...
Journal Article
|
Research

Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa

Taylor WRJ, Naw HK, Maitland K, Williams TN, Kapulu M,  et al.
2018-01-18 • BMC Medicine
2018-01-18 • BMC Medicine
In 2012, the World Health Organization recommended blocking the transmission of Plasmodium falciparum with single low-dose primaquine (SLDPQ, target dose 0.25 mg base/kg body weight), wi...